Table 2.
Baseline characteristics of rule-positive and -negative patients in MOBILITY
| Parameter | Sarilumab 200 mg | Placebo | ||
|---|---|---|---|---|
| Rule-positivea patients (n = 213) | Rule-negative patients (n = 210) | Rule-positivea patients (n = 197) | Rule-negative patients (n = 230) | |
| DAS28-CRP | 6.3 ± 0.8 | 5.7 ± 0.8 | 6.2 ± 0.8 | 5.6 ± 0.8 |
| CDAI | 41.9 ± 12.7 | 39.6 ± 11.4 | 40.5 ± 12.4 | 39.1 ± 12.1 |
| HAQ-DI | 1.8 ± 0.7 | 1.6 ± 0.6 | 1.7 ± 0.6 | 1.5 ± 0.7 |
| SJC28 | 12.6 ± 5.9 | 12.0 ± 5.5 | 11.6 ± 5.5 | 11.4 ± 5.0 |
| Presence of RF, n (%) | 197 (92.5) | 156 (74.6) | 179 (90.9) | 179 (77.8) |
| Presence of anti-CCP, n (%) | 213 (100) | 148 (70.5) | 197 (100) | 168 (73.0) |
| RANKL, pmol/l | 2882 ± 6823 | 1301 ± 1772 | 3111 ± 4437 | 2162 ± 3989 |
| OPG, pmol/l | 6.1 ± 3.0 | 6.2 ± 3.4 | 6.0 ± 3.0 | 5.5 ± 1.8 |
| OC, ng/ml | 19.4 ± 8.4 | 21.3 ± 10.3 | 21.6 ± 12.0 | 21.7 ± 11.9 |
| Prior DMARD use, n (%) | 61 (28.6) | 64 (30.5) | 65 (33.0) | 57 (24.8) |
Values are mean ± SD, unless otherwise indicated
aPatients who were anti-CCP-positive and had CRP > 12.3 mg/l
Anti-CCP anti-cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, DAS28-CRP 28-joint Disease Activity Score using C-reactive protein, HAQ-DI Health Assessment Questionnaire-Disability Index, OC osteocalcin, OPG osteoprotegerin, RANKL receptor activator of NF-kappa B ligand, RF rheumatoid factor, SJC swollen joint count